US FDA Issues Final Guidance On Cybersecurity In Medical Devices

Maryland: The FDA has issued the final guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket SubmissionsThe guidance replaces Content of Premarket Submissions for Management of Cybersecurity in Medical Devices, issued on October 2, 2014.

This document provides recommendations on medical device cybersecurity considerations, device design and labeling, and what information to include in premarket submissions. “These recommendations are intended to promote consistency, facilitate efficient premarket review and help ensure that marketed medical devices are sufficiently resilient to cybersecurity threats,” the FDA states.

The guidance emphasizes that cybersecurity is part of device safety and the quality system requirements found in 21 CFR Part 820, which may be relevant at the premarket stage, postmarket stage or both. It provides recommendations on:

 

  • How connected devices should be tested and validated against breaches that affect multiple connected devices.
  • Provides labeling recommendations for devices with cybersecurity risks.
  • Recommends that companies develop cybersecurity management plans that communicate how they will identify and communicate postmarket vulnerabilities in accordance with 21 CFR 820.100.
  • Recommends that manufacturers provide an updateability and patchability view that describes the end-to-end process that permits software updates and patches to be provided/deployed once the device is in the field.

The guidance recommends that manufacturers use device design processes such as those described in the QS regulation to support secure product development and maintenance. But, to preserve flexibility, they may use other existing frameworks that satisfy the QS regulation and align with FDA’s recommendations for using a Security Product Development Framework (SPDF). Possible frameworks to consider include, but are not limited to, the medical device-specific framework that can be found in the Medical Device and Health IT Joint Security Plan (JSP) 30 and IEC 81001-5-1 or in ANSI/ISA 62443-4-1 Security for industrial automation and control systems Part 4- 1: Product security development life-cycle requirements.

Related Posts

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

A job racket promising appointments as Panchayat Development Officers (PDOs) in the Rural Development and Panchayat Raj Department has come to light after a senior manager of a private pharmaceutical…

Puducherry drugs inspector suspended after counterfeit medicine crackdown

An order issued by Secretary to Government (Health) Choudhary Mohammed Yasin on July 23 stated that Anandakirouchenane, as Drugs Controller, was unable to stop the illegal manufacture of drugs, despite…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Researchers discover a compound that can boost ageing muscle repair

Researchers discover a compound that can boost ageing muscle repair

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit